NCT05985278View on ClinicalTrials.gov

Clinical Application of Lutetium [177Lu]-Catalase in Tumor Radionuclide Therapy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

June 15, 2026

Study Completion Date

June 15, 2026

Conditions
Advanced Malignant Neoplasm
Interventions
DRUG

[ Lu-177]-Catalase

\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks, and the specific dose is related to the size of the tumor

Trial Locations (1)

100142

RECRUITING

Zhi Yang, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER